Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240013/S024

Sphere-9 Catheter

Medtronic, Inc. · Decision date Apr 21, 2026

FDA DECISIONP240013/S024

What did the FDA approve?

FDA records P240013/S024 as a supplement to PMA P240013, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Apr 21, 2026.

FDA approval order statement

the addition of a new warning/precaution statement to the Sphere-9 catheter instructions for use to enhance safety
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Cardiovascular
Decision date
Apr 21, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P240013/S024
Regulatory pathway
PMA supplement
Product code
QZI
Decision code
APPR
Decision date
Apr 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Product code
QZI
FDA device class
3

For the original device and its historical approval scope, see PMA P240013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240013 · Original PMA

    Sphere-9 Catheter and Affera Ablation System

  2. P240013/S012 · Related supplement

    Sphere-9 Catheter and Affera Ablation System (HexaFlow Irrigation Pump; HexaGen RF Generator; HexaPulse PF Generator)

  3. P240013/S014 · Related supplement

    HexaFlow Irrigation Pumo AFR-00004, HexaGen TM RF Generator AFR-00005, HexaPulse TM PF Generator AFR-00008

  4. P240013/S008 · Related supplement

    AFR-00004 HexaGen RF Generator (RFG) and AFR-00008 HexaPulse PF Generator (PFG)

  5. P240013/S013 · Related supplement

    HexaGen RF Generator, HexaPulse PF Generator, HexaFlow Irrigation Pump

  6. P240013/S015 · Related supplement

    Sphere-9 Catheter Mapping and Ablation Catheter

  7. P240013/S010 · Related supplement

    Sphere-9 Mapping and Ablation Catheter

  8. P240013/S016 · Related supplement

    Sphere-9 Catheter and Affera Ablation System

  9. P240013/S017 · Related supplement

    Sphere-9 Catheter and Affera Ablation System

  10. P240013/S018 · Related supplement

    Sphere-9 TM Mapping and Ablation Catheter

  11. P240013/S020 · Related supplement

    Sphere-9 Catheter (AFR-00001)

  12. P240013/S021 · Related supplement

    Sphere-9 Catheter (AFR-00001)

  13. P240013/S024 received

    Application receipt date recorded by FDA.

  14. P240013/S023 · Related supplement

    Sphere-9 Catheter; Tubing Set; Extension Cable

  15. P240013/S024 · FDA decision

    Special (Immediate Track)

  16. P240013/S027 · Related supplement

    Sphere-9 Mapping and Ablation Catheter; Tubing Set; Extension Cable

  17. P240013/S025 · Related supplement

    Sphere-9 Catheter and Affera Ablation System

  18. P240013/S026 · Related supplement

    HexaGen RF Generator Software and Remote

  19. P240013/S029 · Related supplement

    Sphere-9 Catheter and Affera Ablation System

  20. P240013/S030 · Related supplement

    Sphere-9 Catheter AFR-00001

  21. P240013/S031 · Related supplement

    Sphere-9 Catheter and Affera Ablation System

  22. P240013/S028 · Related supplement

    Sphere-9 Catheter and Affera Ablation System

  23. P240013/S032 · Related supplement

    Affera Sphere-9 Mapping and Ablation Catheter

Timeline entries are records held by MedtechLedger for P240013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240013

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalOct 24, 2024FDA
Medtronic, Inc.PMA supplementJul 22, 2025FDA
Medtronic, Inc.PMA supplementJul 23, 2025FDA
Medtronic, Inc.PMA supplementAug 1, 2025FDA
Medtronic, Inc.PMA supplementAug 15, 2025FDA
Medtronic, Inc.PMA supplementAug 29, 2025FDA
Medtronic, Inc.PMA supplementSep 4, 2025FDA
Medtronic, Inc.PMA supplementSep 19, 2025FDA
Medtronic, Inc.PMA supplementOct 7, 2025FDA
Medtronic, Inc.PMA supplementNov 20, 2025FDA
Medtronic, Inc.PMA supplementMar 3, 2026FDA
Medtronic, Inc.PMA supplementMar 6, 2026FDA
Medtronic, Inc.PMA supplementMar 20, 2026FDA
Medtronic, Inc.PMA supplementApr 2, 2026FDA
Medtronic, Inc.PMA supplementMay 13, 2026FDA
Medtronic, Inc.PMA supplementMay 15, 2026FDA
Medtronic, Inc.PMA supplementMay 28, 2026FDA
Medtronic, Inc.PMA supplementJul 10, 2026FDA
Medtronic, Inc.PMA supplementAug 4, 2026FDA
Medtronic, Inc.PMA supplementAug 6, 2026FDA
Medtronic, Inc.PMA supplementOct 2, 2026FDA
Medtronic, Inc.PMA supplementOct 6, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA
Kardium, Inc.PMA supplementOct 27, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records